Accuray and C-RAD unveiled the automated breast cancer treatment package for the Radixact System at ASTRO22. Its unveiling was held on Oct. 23 at the Accuray booth.
"ASTRO 2022 marks an important milestone for our organization as we launch, with C-RAD, a new option for the Radixact System for treating the wide range of breast cancer patients. Breast cancer remains a significant women's health issue that with early detection and more precise treatment technology can have a major impact on extending and improving the quality of patients' lives. It seems appropriate to make this announcement during Breast Cancer Awareness Month, a time when people worldwide join together to raise awareness of improving early diagnosis and treatment options for this disease. This introduction is the result of our strong investment in R&D to deliver robust and differentiated products that are intended to improve lives," said Suzanne Winter, president and chief executive officer of Accuray, pictured (L).
"SGRT technology has proven its substantial benefits in hospitals and clinics around the world, as shown in the multitude of clinical research on the topic. We at C-RAD firmly believe surface tracking is becoming the standard of care," said Tim Thurn, CEO of C-RAD AB, pictured (R). "For breast cancer treatment in particular, our workflow for deep inspiration treatment has fantastic results, both for clinical teams but also for patients. The Accuray DIBH solution on Catalyst+ can be used for a multitude of indications, but for breast cancer treatments the seamless workflow allows deep inspiration treatment on the Radixact System to reduce the dose exposure to the heart amongst other benefits. The goggles as well as the in-room panels help guide the patient through their breathing cycles."